Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API High Quality
Commercial Supple Molnupiravir and Related media with High Quality
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Nomen chemicum | Molnupiravir (EIDD-2801) |
| Synonyma | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxyi-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl) tetrahydrofuran-2 -yl) methyl isobutyrate |
| CAS Number | 2349386-89-4 |
| CATTUS Number | RF-API97 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C13H19N3O7 |
| M. Pondus | 329.31 |
| Solubilitas | Solutum in DMSO |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White pulveris |
| Lepidium sativum IR | Sample Spectrum correspondet relationis vexillum |
| Lepidium sativum HPLC | Retentionis tempus solutionis maioris partis exempli solutionis correspondet solutioni normae |
| Substantiae cognatae | |
| immunditiam A | ≤0.15% |
| impudicitia B | ≤0.15% |
| Quis non specificatus immunditia | ≤0.15% |
| Totalis non specificatae immunditias | ≤0.30% |
| Totalis immunditias | ≤0.50% |
| RELICTUM Solvents | |
| N-Heptane | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Isopropyl Acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| Methylene Dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Aqua Content (KF) | ≤0.50% |
| Residere in Ignition | ≤0.10% |
| Optical gyrationis | -7.5° ad -9.5° (C=0.5, Methanol) |
| Metalla gravis | ≤10ppm |
| Puritas / Analysis Methodus | ≥99.5% (230nm) |
| Asssay / Analysis Methodo | 98.0%~ 102.0% (HPLC in basi exaruit) |
| Fasciae vita | XXIV Menses |
| Test Standard | Enterprise Standard |
| Consuetudinem | API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Molnupiravir (EIDD-2801, MK-4482) est viva monstruosum prodrug ribonucleosidum analogi β-d-N4-hydroxycytidinis (NHC; EIDD-1931) cum lato-spectro antivirali contra SARS-CoV-2, MERS-CoV, SARS-CoV ac causativum COVID-19.Molnupiravir venditur notam nomine Lagevrio et genere ut emorivir.Molnupiravir ostensum est munus pulmonis emendare, corporis pondus minui et quantitatem viri in pulmone minuere.Praeter actionem contra coronaviroses, Molnupiravir in studiis laboratorium actionem contra temporis et avium influentiam demonstravit, virus respiratorii syncytiale, virus chikungunya, virus Ebola, virus equinum venezuelan encephalitis, et virus equinum encephalitis orientalis.Molnupiravir primum elaboratum est ad tractandum influenza in Universitate Emory ab innovatione medicamentorum universitatis societatis, medicamentum Innovationis Ventures apud Emory ( GESTATIO), sed parem mutabilitatem curarum deseruisse.Inde acquisitum est a Miami-substructio comitatu Ridgeback Biotherapeuticorum, quae postea cum Merck & Co. communicavit ut medicamentum ulterius evolveret.Molnupiravir probatus est usui medicorum in Civitate Unita mense Novembri 2021 .
